Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

This is a multi center, open label, long term safety study in pediatric subjects 6 through 17
years of age, inclusive, with a diagnosis of ADHD associated insomnia. Subjects who complete
Study 190 246 (Rollover subjects) and meet the study enrollment criteria will be allowed to
participate in this long term safety study. Additionally, Treatment naïve subjects will be
enrolled in this long term safety study in order to meet the overall subject enrollment
objective of obtaining 100 subjects with 12 months of treatment. This study was previously
posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo
Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals
Inc.

Inclusion Criteria:

Inclusion Criteria:

- Subject is male or female 6 17 years of age, inclusive, at the time of consent.

- Subject must have a diagnosis of ADHD as defined by DSM-IV criteria • The diagnosis
for Rollover subjects will be taken from the Screening visit of Study 190 246.
Treatment naïve subjects will have these assessments performed at the Screening visit.

- Subject must have documented ADHD associated insomnia, defined as the subject or
subject's parent/legal guardian having reported repeated difficulty with sleep
initiation (sleep latency >30 minutes) or consolidation (wake time after sleep onset >
45 minutes),>despite adequate age appropriate time and opportunity for sleep.

- Subject has either >30 minutes latency to persistent sleep (LPS) or >45 minutes wake
time after sleep onset (WASO) demonstrated by PSG.

- Subject or subject's parent/legal guardian should have reported daytime functional
impairment as a result of sleep problems.

- Subject or subject's parent/legal guardian should have reported attempted and failed
behavioral interventions for sleep problems, including a regular bedtime and rise
time.

- Subject's sleep disturbance must not be attributable to either the direct physiologic
effect of a drug of abuse or misuse of a prescribed medication whether it is being
used as intended or in an illicit manner.

- Female subjects ≥8 years of age must have a negative serum pregnancy test at screening

- Subject must be in good general health.

- Subject must be able to swallow tablets.

- If subjects are currently taking medication for ADHD, they must be on a stable dose
and regimen for at least one month, and preferably for at least 3 months prior to the
time of consent

Exclusion Criteria:

- Subject with weight <10th percentile for age and gender

- Subject has any clinically significant or unstable medical abnormality/illness

- Subject has a documented history of Bipolar I or II Disorder, major depression,
conduct disorder, generalized anxiety disorder (other than obsessive-compulsive
disorder) or any history of psychosis, as determined by medical or psychiatric history
or as determined by clinical interview using the MINI-Kid at Visit 1.

- Subject has periodic limb movement >5 times per hour, as demonstrated on PSG.

- Subject has sleep disordered breathing, as demonstrated on PSG.

- Subject has another primary sleep disorder (or secondary sleep disorder that is
causing clinical impairment or any other known or suspected medical or psychiatric
condition that has affected or may affect sleep

- Subject has a history of circadian rhythm disorder or will travel across ≥3 time zones
more than once during the study.

- Subject has organic brain disease, or a history of febrile seizures.

- Subject is, in the opinion of the investigator, at suicidal or homicidal risk.

- Female subject who is pregnant, lactating or planning to become pregnant.

- Subject is taking any psychotropic or disallowed medications,

- Subject has a history of severe allergies to more than 1 class of medications or
multiple adverse drug reactions.

- Subject has a history of allergic reaction or has a known or suspected sensitivity to
racemic zopiclone, eszopiclone, or any substance that is contained in the formulation.

- Subject has a history of alcohol or substance abuse within 3 months of study
participation

- Subject has participated in any investigational study within 30 days prior to study
entry or is currently participating in another clinical trial, except Study 190 246.